{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:27:05Z","timestamp":1790872025706,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejim.2023.10.032","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:03:56Z","timestamp":1698797036000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Non-conventional immunomodulation in the management of sepsis"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6281-040X","authenticated-orcid":false,"given":"M.A.","family":"Slim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-9915","authenticated-orcid":false,"given":"O.","family":"Turgman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"van Vught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1343","authenticated-orcid":false,"given":"W.J.","family":"Wiersinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejim.2023.10.032_bib0001","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejim.2023.10.032_bib0002","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejim.2023.10.032_bib0003","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.ejim.2023.10.032_bib0004","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejim.2023.10.032_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104363","article-title":"Immunopathophysiology of human sepsis","volume":"86","author":"Wiersinga","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejim.2023.10.032_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107476","article-title":"Immunotherapy in sepsis - brake or accelerate?","volume":"208","author":"Steinhagen","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0007","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S1473-3099(19)30567-5","article-title":"Current gaps in sepsis immunology: new opportunities for translational research","volume":"19","author":"Rubio","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0008","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/1751143718765407","article-title":"Immune therapy in sepsis: are we ready to try again?","volume":"19","author":"Davies","year":"2018","journal-title":"J Intensive Care Soc"},{"issue":"8","key":"10.1016\/j.ejim.2023.10.032_bib0009","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/jcm12082892","article-title":"Treatment advances in sepsis and septic shock: modulating pro- and anti-inflammatory mechanisms","volume":"12","author":"Marques","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.10.032_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1473-3099(01)00093-7","article-title":"Immunotherapy of sepsis","volume":"1","author":"van der Poll","year":"2001","journal-title":"The Lancet Infectious Diseases"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00005-016-0415-9","article-title":"Immunotherapy of sepsis: blind alley or call for personalized assessment?","volume":"65","author":"Prucha","year":"2017","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067251","article-title":"ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol","volume":"12","author":"Kotsaki","year":"2022","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0013","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","article-title":"Immunomodulation by macrolides: therapeutic potential for critical care","volume":"8","author":"Reijnders","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13054-022-04055-4","article-title":"Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial","volume":"26","author":"Karakike","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.ejim.2023.10.032_bib0015","unstructured":"Liu, S., et\u00a0al., Effect of an herbal-based injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial. JAMA Intern Med, 2023."},{"issue":"9","key":"10.1016\/j.ejim.2023.10.032_bib0016","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamainternmed.2016.2514","article-title":"Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial","volume":"176","author":"Bloos","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0017","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","article-title":"Norepinephrine dysregulates the immune response and compromises host defense during sepsis","volume":"202","author":"Stolk","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0018","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13613-015-0071-y","article-title":"The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial","volume":"5","author":"Chelkeba","year":"2015","journal-title":"Ann Intensive Care"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0019","doi-asserted-by":"crossref","first-page":"R271","DOI":"10.1186\/cc13106","article-title":"The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis","volume":"17","author":"Kushimoto","year":"2013","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.1963.63700060029012","article-title":"The effectiveness of hydrocortisone in the management of severe infections: a double-blind study","volume":"183","year":"1963","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0021","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1172\/JCI200319523","article-title":"The enigma of sepsis","volume":"112","author":"Riedemann","year":"2003","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ejim.2023.10.032_bib0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00000658-197609000-00011","article-title":"Steroids in the treatment of clinical septic shock","volume":"184","author":"Schumer","year":"1976","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2023.10.032_bib0023","first-page":"39","article-title":"Succesful treatment of human gram-negative bacteremia with antiserum against endotoxin core","volume":"94","author":"Ziegler","year":"1981","journal-title":"Trans Assoc Am Phys"},{"issue":"20","key":"10.1016\/j.ejim.2023.10.032_bib0024","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJM198211113072001","article-title":"Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli","volume":"307","author":"Ziegler","year":"1982","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-121-1-199407010-00001","article-title":"Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group","volume":"121","author":"McCloskey","year":"1994","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.ejim.2023.10.032_bib0026","first-page":"339","article-title":"Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis\u2013a prospective randomized study","volume":"272","author":"Grundmann","year":"1988","journal-title":"Prog Clin Biol Res"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0027","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/infdis\/158.2.312","article-title":"Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial","volume":"158","author":"Calandra","year":"1988","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0028","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.clinthera.2021.12.008","article-title":"Efficacy of intravenous immunoglobulin therapy for patients with sepsis and low immunoglobulin G levels: a single-center retrospective study","volume":"44","author":"Akatsuka","year":"2022","journal-title":"Clin Ther,"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0029","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","article-title":"Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial","volume":"273","author":"Abraham","year":"1995","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ejim.2023.10.032_bib0030","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Phase III rhIL-1ra sepsis syndrome study group., recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejim.2023.10.032_bib0031","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1097\/01.CCM.0000145229.59014.6C","article-title":"Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels","volume":"32","author":"Panacek","year":"2004","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0032","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.ejim.2023.10.032_bib0033","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","article-title":"A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis","volume":"38","author":"Rice","year":"2010","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0034","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/CCM.0b013e3181b07b78","article-title":"Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis","volume":"38","author":"Tidswell","year":"2010","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/SHK.0b013e318227980e","article-title":"Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis","volume":"36","author":"Kalil","year":"2011","journal-title":"Shock"},{"issue":"11","key":"10.1016\/j.ejim.2023.10.032_bib0036","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","article-title":"Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial","volume":"309","author":"Opal S","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2023.10.032_bib0037","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-physiol-061121-040214","article-title":"Sepsis-Induced Immunosuppression","volume":"84","author":"Torres","year":"2022","journal-title":"Annu Rev Physiol"},{"issue":"23","key":"10.1016\/j.ejim.2023.10.032_bib0038","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejim.2023.10.032_bib0039","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","article-title":"The immunology of sepsis","volume":"54","author":"van der Poll","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0040","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.CCM.0B013E318161E480","article-title":"Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock","volume":"36","author":"Stephens","year":"2008","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0041","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archsurg.141.2.150","article-title":"Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial","volume":"141","author":"Orozco","year":"2006","journal-title":"Arch Surg"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0042","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archinte.1997.00440250031004","article-title":"Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle","volume":"157","author":"Kox","year":"1997","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0043","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nm0697-678","article-title":"Monocyte deactivation in septic patients: restoration by IFN-gamma treatment","volume":"3","author":"D\u00f6cke","year":"1997","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.ejim.2023.10.032_bib0044","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/00003246-200207000-00015","article-title":"Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma","volume":"30","author":"Nakos","year":"2002","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0045","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00134-003-1731-1","article-title":"Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial","volume":"29","author":"Dhainaut","year":"2003","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004388.pub5","article-title":"Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients","author":"Mart\u00ed-Carvajal","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1016\/j.ejim.2023.10.032_bib0047","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0048","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0049","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13613-023-01109-w","article-title":"Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial","volume":"13","author":"Daix","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0050","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.ejim.2023.10.032_bib0051","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0052","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SHK.0000000000001443","article-title":"Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1\/2 study","volume":"53","author":"Watanabe","year":"2020","journal-title":"Shock"},{"key":"10.1016\/j.ejim.2023.10.032_bib0053","article-title":"Traditional Chinese medicine for treatment of sepsis and related multi-organ injury","volume":"14","author":"Song","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2023.10.032_bib0054","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/759748","article-title":"Traditional chinese medicine diagnosis \"yang-xu zheng\": significant prognostic predictor for patients with severe sepsis and septic shock","volume":"2013","author":"Lin","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.ejim.2023.10.032_bib0055","article-title":"Traditional Chinese Medicine: a promising strategy to regulate inflammation, intestinal disorders and impaired immune function due to sepsis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2023.10.032_bib0056","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jep.2017.10.001","article-title":"Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis","volume":"211","author":"Chen","year":"2018","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0057","first-page":"36","article-title":"Effects of xuebijing injection for patients with sepsis-induced acute kidney injury after wenchuan earthquake","volume":"23","author":"Yuxi","year":"2017","journal-title":"Altern Ther Health Med"},{"issue":"8","key":"10.1016\/j.ejim.2023.10.032_bib0058","first-page":"10029","article-title":"Efficacy of Xuebijing injection in the adjunctive therapy of acute respiratory distress syndrome caused by sepsis","volume":"12","author":"Zhen","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ejim.2023.10.032_bib0059","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/949254","article-title":"Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation","volume":"2014","author":"Yin","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"10.1016\/j.ejim.2023.10.032_bib0060","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1097\/CCM.0000000000003842","article-title":"XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial","volume":"47","author":"Song","year":"2019","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ejim.2023.10.032_bib0061","doi-asserted-by":"crossref","unstructured":"Lao, X. and J. Rello, Efficacy of Xuebijing injection for sepsis (EXIT-SEP): lost in translation. 2023. p. 101257.","DOI":"10.1016\/j.accpm.2023.101257"},{"issue":"7","key":"10.1016\/j.ejim.2023.10.032_bib0062","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamainternmed.2023.0788","article-title":"Xuebijing injection for the treatment of sepsis: what would a path to FDA approval look like?","volume":"183","author":"Unger","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2023.10.032_bib0063","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jep.2019.01.008","article-title":"Effect of Shenfu injection on lipopolysaccharide (LPS)-induced septic shock in rabbits","volume":"234","author":"Liu","year":"2019","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"10.1016\/j.ejim.2023.10.032_bib0064","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/SHK.0000000000001975","article-title":"Effects of Shenfu injection on sublingual microcirculation in septic shock patients: a randomized controlled trial","volume":"58","author":"Wang","year":"2022","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajem.2016.09.008","article-title":"Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock","volume":"35","author":"Zhang","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0066","first-page":"35","article-title":"Effect of Septimeb(TM) as a new natural extract on severe sepsis: a randomized clinical trial","volume":"8","author":"Pourdast","year":"2017","journal-title":"Caspian J Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0067","doi-asserted-by":"crossref","DOI":"10.1186\/2008-2231-20-40","article-title":"Positive effect of septimeb\u2122 on mortality rate in severe sepsis: a novel non antibiotic strategy","volume":"20","author":"Eslami K","year":"2012","journal-title":"Daru"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0068","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3923\/ajava.2011.1185.1192","article-title":"Setarud (IMOD (TM)) as a multiherbal drug with promising benefits in animal and human studies: a comprehensive review of biochemical and cellular evidences","volume":"6","author":"Mohammadirad","year":"2011","journal-title":"Asian J Anim Vet Adv"},{"key":"10.1016\/j.ejim.2023.10.032_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.116040","article-title":"Mechanisms of JinHong Formula on treating sepsis explored by randomized controlled trial combined with network pharmacology","volume":"305","author":"Wu","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.ejim.2023.10.032_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1079482","article-title":"Jinhong decoction protects sepsis-associated acute lung injury by reducing intestinal bacterial translocation and improving gut microbial homeostasis","volume":"14","author":"Bao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0071","doi-asserted-by":"crossref","first-page":"12456","DOI":"10.21037\/apm-21-3179","article-title":"Effect of traditional Chinese medicine on serum inflammation and efficacy in patients with sepsis: a systematic review and meta-analysis","volume":"10","author":"Wen","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0072","doi-asserted-by":"crossref","first-page":"122","DOI":"10.21037\/atm.2018.12.23","article-title":"Clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for sepsis","volume":"7","author":"Zhao","year":"2019","journal-title":"Ann Transl Med"},{"issue":"7407","key":"10.1016\/j.ejim.2023.10.032_bib0073","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/bmj.327.7407.117","article-title":"Immunonutrition","volume":"327","author":"Calder","year":"2003","journal-title":"BMJ"},{"issue":"9225","key":"10.1016\/j.ejim.2023.10.032_bib0074","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(00)02490-9","article-title":"The importance of selenium to human health","volume":"356","author":"Rayman","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0075","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm0595-433","article-title":"Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates","volume":"1","author":"Beck","year":"1995","journal-title":"Nat Med"},{"issue":"11\u201312","key":"10.1016\/j.ejim.2023.10.032_bib0076","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00508-013-0371-x","article-title":"Restoration of antioxidant enzymes in the therapeutic use of selenium in septic patients","volume":"125","author":"Janka","year":"2013","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0077","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00134-011-2153-0","article-title":"High-dose selenium substitution in sepsis: a prospective randomized clinical trial","volume":"37","author":"Valenta","year":"2011","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0078","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clnu.2006.10.003","article-title":"Effect of selenium supplementation on biochemical markers and outcome in critically ill patients","volume":"26","author":"Mishra","year":"2007","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ejim.2023.10.032_bib0079","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcrc.2019.05.001","article-title":"Immune function testing in sepsis patients receiving sodium selenite","volume":"52","author":"Guo","year":"2019","journal-title":"J Crit Care"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-199855040-00001","article-title":"Lipid mediators in inflammatory disorders","volume":"55","author":"Heller","year":"1998","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejim.2023.10.032_bib0081","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.200207-674OC","article-title":"Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis","volume":"167","author":"Mayer","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0082","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/cc8844","article-title":"Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial","volume":"14","author":"Barbosa","year":"2010","journal-title":"Crit Care"},{"issue":"8","key":"10.1016\/j.ejim.2023.10.032_bib0083","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00003246-199908000-00001","article-title":"Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral nutrition in ARDS study group","volume":"27","author":"Gadek","year":"1999","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.10.032_bib0084","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0148607113518945","article-title":"A randomized controlled trial investigating the effects of parenteral fish oil on survival outcomes in critically ill patients with sepsis: a pilot study","volume":"39","author":"Hall","year":"2015","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/0884533611418783","article-title":"Comparison of the effects of different intravenous fat emulsions in patients with systemic inflammatory response syndrome and sepsis","volume":"26","author":"Sungurtekin","year":"2011","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.ejim.2023.10.032_bib0086","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fphar.2020.00487","article-title":"Nanocurcumin: a promising candidate for therapeutic applications","volume":"11","author":"Karthikeyan","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ejim.2023.10.032_bib0087","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1039\/D1FO03746C","article-title":"Nano-curcumin supplementation in critically ill patients with sepsis: a randomized clinical trial investigating the inflammatory biomarkers, oxidative stress indices, endothelial function, clinical outcomes and nutritional status","volume":"13","author":"Karimi","year":"2022","journal-title":"Food Funct"},{"key":"10.1016\/j.ejim.2023.10.032_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1037861","article-title":"Evaluating the effects of curcumin nanomicelles on clinical outcome and cellular immune responses in critically ill sepsis patients: a randomized, double-blind, and placebo-controlled trial","volume":"9","author":"Karimi","year":"2022","journal-title":"Front Nutr"},{"issue":"9","key":"10.1016\/j.ejim.2023.10.032_bib0089","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1097\/CCM.0000000000001148","article-title":"Effect of cholecalciferol supplementation on vitamin d status and cathelicidin levels in sepsis: a randomized, placebo-controlled trial","volume":"43","author":"Quraishi","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ejim.2023.10.032_bib0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clnesp.2018.10.011","article-title":"Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial","volume":"29","author":"Cherukuri","year":"2019","journal-title":"Clin Nutr ESPEN"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0091","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1164\/rccm.201405-0988OC","article-title":"Randomized controlled trial of calcitriol in severe sepsis","volume":"190","author":"Leaf","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0092","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17471060701682260","article-title":"Immunomodulatory effects of glutamine-enriched nutritional support in elderly patients with severe sepsis: a prospective, randomized, controlled study","volume":"4","author":"Cai","year":"2008","journal-title":"J Organ Dysfunct"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0093","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.nut.2011.07.011","article-title":"Enteral nutrition supplemented with l-glutamine in patients with systemic inflammatory response syndrome due to pulmonary infection","volume":"28","author":"Cavalcante","year":"2012","journal-title":"Nutrition"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0094","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5492\/wjccm.v11.i6.349","article-title":"Current role of high dose vitamin C in sepsis management: a concise review","volume":"11","author":"Juneja","year":"2022","journal-title":"World J Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2019.22176","article-title":"Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the vitamins randomized clinical trial","volume":"323","author":"Fujii","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ejim.2023.10.032_bib0096","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jama.2020.11946","article-title":"Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial","volume":"324","author":"Moskowitz","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0097","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4049\/jimmunol.145.5.1430","article-title":"Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor","volume":"145","author":"Spengler","year":"1990","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0098","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1164\/rccm.201604-0862CP","article-title":"Potentially inadvertent immunomodulation: norepinephrine use in sepsis","volume":"194","author":"Stolk","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ejim.2023.10.032_bib0099","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.4049\/jimmunol.159.10.4857","article-title":"Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production","volume":"159","author":"Ramer-Quinn","year":"1997","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/cc2879","article-title":"Clinical review: immunomodulatory effects of dopamine in general inflammation","volume":"8","author":"Beck","year":"2004","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.ejim.2023.10.032_bib0101","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/cc8034","article-title":"Immunosedation: a consideration for sepsis","volume":"13","author":"MacLaren","year":"2009","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0102","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/cc8012","article-title":"Sedation improves early outcome in severely septic Sprague Dawley rats","volume":"13","author":"Qiao","year":"2009","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.ejim.2023.10.032_bib0103","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/cc8916","article-title":"Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial","volume":"14","author":"Pandharipande","year":"2010","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0104","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13054-020-03207-8","article-title":"Effect of dexmedetomidine on inflammation in patients with sepsis requiring mechanical ventilation: a sub-analysis of a multicenter randomized clinical trial","volume":"24","author":"Ohta","year":"2020","journal-title":"Crit Care"},{"issue":"15","key":"10.1016\/j.ejim.2023.10.032_bib0105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1056\/NEJMoa2024922","article-title":"Dexmedetomidine or propofol for sedation in mechanically ventilated adults with sepsis","volume":"384","author":"Hughes","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.10.032_bib0106","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccc.2009.05.001","article-title":"Sedation & immunomodulation","volume":"25","author":"Sanders","year":"2009","journal-title":"Crit Care Clin"},{"issue":"5 Pt 1","key":"10.1016\/j.ejim.2023.10.032_bib0107","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF03009871","article-title":"Propofol inhibits phagocytosis and killing of Staphylococcus aureus and Escherichia coli by polymorphonuclear leukocytes in vitro","volume":"41","author":"Krumholz","year":"1994","journal-title":"Can J Anaesth"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0108","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1034\/j.1399-6576.1999.430115.x","article-title":"Alterations of bacterial clearance induced by propofol","volume":"43","author":"Kelbel","year":"1999","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.ejim.2023.10.032_bib0109","doi-asserted-by":"crossref","unstructured":"Young, P.J., et\u00a0al., Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med, 2012.","DOI":"10.1016\/j.ymed.2012.08.026"},{"issue":"4","key":"10.1016\/j.ejim.2023.10.032_bib0110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CCM.0000000000002249","article-title":"Fever in the emergency department predicts survival of patients with severe sepsis and septic shock admitted to the ICU","volume":"45","author":"Sunden-Cullberg","year":"2017","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0111","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13054-016-1510-3","article-title":"Risk factors, host response and outcome of hypothermic sepsis","volume":"20","author":"Wiewel","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.ejim.2023.10.032_bib0112","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3906032","article-title":"Effects of target temperature management on the outcome of septic patients with fever","volume":"2017","author":"Gao","year":"2017","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.ejim.2023.10.032_bib0113","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/CCM.0000000000005470","article-title":"Therapeutic hyperthermia is associated with improved survival in afebrile critically ill patients with sepsis: a pilot randomized trial","volume":"50","author":"Drewry","year":"2022","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.10.032_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170152","article-title":"Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials","volume":"12","author":"Rumbus","year":"2017","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ejim.2023.10.032_bib0115","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/CCM.0000000000004935","article-title":"The effect of early sedation with dexmedetomidine on body temperature in critically ill patients","volume":"49","author":"Grayson","year":"2021","journal-title":"Crit Care Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:58:06Z","timestamp":1737604686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523003874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":115,"alternative-id":["S0953620523003874"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.10.032","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-conventional immunomodulation in the management of sepsis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}